醒脑静注射液与依达拉奉的草药-药物相互作用:药代动力学、UGT混合抑制与分子对接研究
醒脑静注射液(XNJ)常与依达拉奉(EDA)联用治疗急性缺血性脑卒中,但可能引发草药-药物相互作用。大鼠GC-MS药代动力学显示,XNJ使(-)-冰片AUC0-∞增加1.25倍(EDA+XNJ 10分钟后),EDA使依达拉奉Cmax增加1.6倍(XNJ+EDA 10分钟后,p<0.05)。体外实验表明XNJ及(-)-冰片混合抑制UGT2B7和UGT1A6,Ki分别为101.393和136.217 μM。
要点
- XNJ与EDA联用可改变彼此药代动力学,增加暴露量。
- (-)-冰片通过混合抑制UGT2B7和UGT1A6介导相互作用。
- 临床联用XNJ与UGT2B7/UGT1A6底物药物需谨慎。
核心结论
- (-)-冰片通过混合抑制UGT2B7和UGT1A6调节依达拉奉的药代动力学行为,为XNJ与EDA联用的协同作用提供理论依据。
- 当XNJ与UGT2B7和UGT1A6底物联用时,临床应谨慎使用。
研究设计与样本
- 大鼠体内GC-MS药代动力学研究,结合体外LC-MS/MS测定XNJ及(-)-冰片对UGTs的抑制作用。
- 采用体外-体内外推(IVIVE)和分子对接揭示草药-药物相互作用潜力。
主要发现
- EDA+XNJ 10分钟后组(-)-冰片AUC0-∞增加1.25倍;XNJ+EDA 10分钟后组依达拉奉Cmax增加1.6倍(p<0.05)。
- XNJ和(-)-冰片在HLM和RLM中抑制UGTs介导的依达拉奉代谢,抑制强度相似,且在RLM中更强。
- (-)-冰片以混合抑制机制中度抑制UGT2B7和UGT1A6,Ki值分别为101.393和136.217 μM。
- (-)-冰片与依达拉奉对UGT2B7的结合能分别为-6.254和-6.643 kcal/mol,对UGT1A6的评分分别为-5.220和-6.469 kcal/mol。
- (-)-冰片与许多经UGT2B7和UGT1A6代谢的药物具有相似的自由能。
关键数值与推荐
- (-)-冰片抑制UGT2B7的Ki值为101.393 μM,抑制UGT1A6的Ki值为136.217 μM,均为混合抑制机制。
- EDA+XNJ 10分钟后组(-)-冰片AUC0-∞增加1.25倍;XNJ+EDA 10分钟后组依达拉奉Cmax增加1.6倍(p<0.05)。
临床怎么用
- 临床联用XNJ与依达拉奉时,需关注因UGTs抑制导致的暴露量增加及不良反应风险。
- XNJ与经UGT2B7或UGT1A6代谢的药物联用时,应谨慎并加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xingnaojing injection (XNJ) is a famous emergency Traditional Chinese medicine (TCM) derived from the classical Chinese prescription named An-Gong-Niu-Huang Pill. XNJ is often used along with Edaravone injection (EDA) to treat acute ischemic stroke, they have a synergistic effect in improving patients' blood coagulation and neurological function. However, this combination also causes herb-drug interactions (HDIs), raising the risk of adverse reactions. At present, little is known about the pharmacokinetics and potential mechanism of XNJ combined with EDA. PURPOSE: This study investigates the pharmacokinetics and potential mechanism of the HDIs between XNJ and EDA. STUDY DESIGN AND METHODS: The pharmacokinetic interactions between XNJ and EDA were studied by GC-MS in rats, and the inhibition of XNJ and (-)-borneol on UDP-glucuronosyltransferase (UGTs) were assayed by LC-MS/MS in vitro. In vitro-in vivo extrapolation (IVIVE) and molecular docking were performed to reveal the potential for HDIs. RESULTS: The AUC0-∞ of (-)-borneol was increased by 1.25-fold in group EDA+XNJ 10 min later, and the Cmax of edaravone was increased by 1.6-fold in group XNJ+EDA 10 min later (p < 0.05). XNJ and (-)-borneol inhibited UGTs-mediated edaravone metabolism in HLM and RLM with a similar inhibitory intensity, in which both of them have stronger inhibition in RLM. These findings demonstrated that (-)-borneol in XNJ mainly exerted UGTs inhibition, which was consistent with the pharmacokinetic assays. (-)-Borneol moderately inhibited UGT2B7 and UGT1A6 by a mixed inhibition mechanism, with Ki values of 101.393 and 136.217 μM, respectively. Due to the blood concentration of injection was dramatically increased, the HDIs caused by the inhibitory effect of XNJ on UGTs should be highly emphasized. The binding energies of (-)-borneol and edaravone toward UGT2B7 were -6.254 and -6.643 kcal/mol, and the scores towards UGT1A6 were -5.220 and -6.469 kcal/mol, respectively. Moreover, (-)-borneol has similar free energies to many drugs metabolized by UGT2B7 and UGT1A6. CONCLUSIONS: (-)-Borneol modulates the pharmacokinetic behavior of edaravone via mixed inhibition of UGT2B7 and UGT1A6. It provides a theoretical basis for the synergistic effect of XNJ and EDA combinations in clinical practice. When XNJ is used along with UGT2B7 and UGT1A6 substrates, it should be used clinically with caution.
引用
- Qi D, Li H, Liang C, et al. Herb-drug interaction of Xingnaojing injection and Edaravone via pharmacokinetics, mixed inhibition of UGTs, and molecular docking. Phytomedicine. 2023. PMID: 36764095. doi:10.1016/j.phymed.2023.154696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。